People · Operator
Named in public records as an officer, director or promoter · active 2012–2026 · Other, Biotechnology, Pharmaceuticals, Software / Tech, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Freenome Holdings, Inc. | — | Other | Series D+ | $750.6M | $3.4B | 2021 |
| Vaxess Technologies, Inc. | — | Biotechnology | Series C | $138.2M | $269.9M | 2021 |
| Nature's Toolbox, Inc. | — | Biotechnology | Series C | $82.0M | $54.5M | 2025 |
| ARS Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $63.0M | $1.3B | 2021 |
| Lantos Technologies, Inc. | — | Software / Tech | Series A | $52.3M | $24.1M | 2015 |
| Cellscape Corp | — | Other | Series A | $21.3M | $128.6M | 2012 |
| Calimmune, Inc. | — | Biotechnology | Series B | $15.9M | $629.2M | 2015 |
| Adeo Health Science, Inc. | — | Healthtech | Seed | $5.4M | $85.4M | 2017 |
Peter Kolchinsky at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter Kolchinsky on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Amir Nashat | 1 | 14 |
| Jonathan Leff | 1 | 11 |
| Ann DeWitt | 1 | 10 |
| Vijay Pande | 1 | 9 |
| Michael Borrus | 1 | 7 |
| Rajeev Dadoo | 1 | 7 |
| Aaron Sandoski | 1 | 7 |
| Adam Rosenberg | 1 | 6 |
| Darshana Zaveri | 1 | 5 |
| Brent Saunders | 1 | 5 |
| Pratik Shah | 1 | 5 |
| Karen Drexler | 1 | 4 |
| Charles Roberts | 1 | 4 |
| Joshua S. Phillips | 1 | 4 |
| Randal Scott | 1 | 4 |
| Rachel Sha | 1 | 4 |
| Joshua Phillips | 1 | 4 |
| Harry A. George | 1 | 3 |
| Purnanand Sarma | 1 | 3 |
| Andrew Galligan | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.